Table 2: Changes in echocardiographic parameters during the intervention.
| Variable | Atorvastatin group | Placebo group | p Within group | p Between group | ||
| Before | After | Before | After | |||
| Mid RV diameter (cm) | 3.6 (1.13)‡ | 3.07 ± 0.23 | 3.61 ± 0.69 | 3.12 ± 0.21 | 0.37 | 0.40 |
| RA area (cm2) | 14.88 ± 2.04 | 15.04 ± 1.92 | 14.77 ± 1.92 | 14.97 ± 0.48 | 0.91 | 0.85 |
| LVEF (%) | 56.93 ± 3.70 | 57.09 ± 3.39 | 57.53 ± 2.46 | 57.92 ± 1.98 | 0.63 | 0.37 |
| SM (cm/sec) | 10.72 ± 1.61 | 11.12 ± 1.85 | 10.68 ± 1.21 | 10.96 ± 0.93 | 0.73 | 0.78 |
| TA EM (cm/sec) | 8.64 ± 1.97 | 8.85 ± 1.97 | 8.70 ± 1.99 | 9.10 ± 1.93 | 0.73 | 0.74 |
| TA AM (cm/sec) | 16.29 ± 2.92 | 15.45 ± 2.14 | 14.89 ± 2.53 | 15.16 ± 1.89 | 0.19 | 0.10 |
| TVE (m/sec) | 38.16 ± 7.01 | 38.97 ± 8.13 | 41.20 ± 7.20 | 40.27 ± 3.59 | 0.30 | 0.20 |
| TV E/TA EM | 4.90 ± 1.19 | 0.55 ± 0.12 | 5.27 ± 1.52 | 0.60 ± 0.13 | 0.42 | 0.24 |
| RV SRB | - 24.19 ± 2.66a | - 26.71 ± 3.7ab | -23.65 ± 2.59 | - 24.31 ± 2.92b | 0.08 | 0.03* |
| RV SRM | - 29.96 ± 2.88c | - 32.69 ± 3.64c | -30.49 ± 3.92 | - 30.88 ± 4.14 | 0.03* | 0.44 |
| PAP | 38.49 ± 7.15d | 34.51 ± 6.61d | 34.74 ± 8.33 | 35.15 ± 10.07 | 0.01* | 0.44 |
| GLS | - 15.11 ± 6.77 | - 18.13 ± 1.68 | -16.40 ± 1.22 | - 18.12 ± 1.62 | 0.76 | 0.39 |
| hsCRP | 3.39(8.69) | 3.30(5.22)e | 4.20(5.14) | 6.97(10.33)e | 0.95 | 0.03* |
GLS: Global Longitudinal Strain; LVEF: Left Ventricle Ejection Fraction; PAP: Pulmonary Artery Pressure; RA: Right Atrium; RV: Right Ventricle; SRB: Longitudinal Strain in Basal Segment of RV Free Wall; SRM: Longitudinal Strain in Mid Segment of RV Free Wall; TA: Tricuspid Annulus; TV: Tricuspid Valve.
‡Median and interquartile range (IQR) were shown; *Significant difference; ap < 0.001; bp = 0.01; cp < 0.001; dp = 0.001; ep = 0.04.